Bengaluru, Apr 20: MicrobioTx announced the launch of its innovative Irritable Bowel Syndrome (IBS) Risk Score, a predictive solution designed to assess an individual’s likelihood of developing Irritable Bowel Syndrome. The launch coincides with IBS Awareness Month in April, reinforcing the need for greater awareness and early intervention in managing gut health.
IBS is among the most common yet underdiagnosed gastrointestinal disorders in India, affecting an estimated 4–8% of the population—approximately 40 to 80 million people. Despite its prevalence, the condition lacks a definitive diagnostic test and is typically identified based on symptoms such as abdominal pain, bloating, cramping, and altered bowel habits. This often results in delayed diagnosis, mismanagement, and prolonged patient discomfort, with many individuals not seeking timely medical care.
MicrobioTx’s IBS Risk Score leverages advanced gut microbiome profiling combined with metabolite analysis—biological signals released by microbes into the bloodstream to provide deeper insights into an individual’s gut health. By analysing these markers, the solution identifies patterns associated with IBS, enabling early risk detection and supporting more informed clinical decisions.
The new offering builds on the company’s ongoing research in Microbiome Science and follows a recently concluded clinical study conducted in collaboration with Maulana Azad Medical College. The study validated the high accuracy of MicrobioTx’s Gut Function Test (GFT) for Indian IBS patients, demonstrating strong predictive capabilities in identifying both general and IBS-specific microbiome imbalances.
Commenting on the development, Dr. Ujjwal Sonika, Professor of Gastroenterology at Maulana Azad Medical College and principal investigator of the study, said,
“IBS is a prevalent and underdiagnosed condition. Gut dysbiosis is an important contributing factor in its development and represents a potential therapeutic opportunity.”
The IBS Risk Score utilizes insights from the clinical study to analyze microbiome and metabolic profiles, helping clinicians determine whether an individual’s gut composition aligns with patterns associated with IBS. This enables a shift from reactive diagnosis to proactive risk assessment, paving the way for earlier interventions and improved patient outcomes.
The launch underscores MicrobioTx’s commitment to advancing accessible, science-backed microbiome solutions and delivering affordable, clinically relevant innovations in gut health.
